The Evolving Definition of Alzheimer’s: A Neuropathological Perspective
A recent reader response in Neurology reinforces the critical position that Alzheimer disease is a specific disorder defined by its underlying neuropathology, which is increasingly detectable during a patient’s lifetime. This perspective underscores a fundamental shift in diagnostic paradigms, moving beyond purely clinical symptoms to incorporate biomarkers and advanced imaging that reveal hallmark pathological features like amyloid plaques and tau tangles. The discussion highlights the ongoing refinement of diagnostic criteria to integrate these objective pathological measures, aiming for greater accuracy in identifying the disease and distinguishing it from other forms of dementia.
Study Significance: For pathologists and molecular diagnosticians, this debate centers on the validation and clinical integration of biomarkers as proxies for traditional post-mortem tissue analysis. The push for in vivo detection of pathology directly impacts laboratory medicine, driving demand for precise assays in cerebrospinal fluid and advanced imaging interpretations that serve as digital biopsies. This evolution necessitates close collaboration between clinical pathology and neurology to standardize these diagnostic tools, ultimately influencing patient stratification for targeted therapies and clinical trial design.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
